Lyndra Therapeutics
Clinical-stage biopharmaceutical company developing long-acting oral therapies that can deliver medications for a week or longer in a single dose, improving medication adherence and patient outcomes.
Notes
Lyndra Therapeutics is a clinical-stage biopharmaceutical company revolutionizing drug delivery through its proprietary LYNX platform, which enables oral medications to be administered once weekly instead of daily. The company's technology uses a unique dosage form that safely resides in the stomach for extended periods, gradually releasing medication.
Founded by MIT researchers, Lyndra is developing treatments across multiple therapeutic areas including neuropsychiatry, infectious diseases, and metabolic conditions where medication adherence is a significant challenge.
Team
- Patricia Hurter, Ph.D. - Chief Executive Officer
- LinkedIn: linkedin.com/in/patricia-hurter
- Giovanni Traverso, M.D., Ph.D. - Co-Founder, Scientific Advisory Board (MIT/BWH)
- Robert Langer, Sc.D. - Co-Founder (MIT)
Additional Research Findings
- Founded in 2015
- Headquarters in Watertown, Massachusetts
- Portfolio company of Polaris Partners
- Co-founded by MIT's Robert Langer and Giovanni Traverso
- Proprietary LYNX platform for weekly oral dosing
- Lead programs in HIV treatment and neuropsychiatric conditions
- Addressing medication adherence challenges
- Raised over $200M in funding
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |